• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection†

  1. Florian van Bömmel1,
  2. Thomas Wünsche2,
  3. Stefan Mauss3,
  4. Petra Reinke4,
  5. Alexandra Bergk1,
  6. Dirk Schürmann2,
  7. Bertram Wiedenmann1,
  8. Thomas Berg1,‡,*

Article first published online: 24 NOV 2004

DOI: 10.1002/hep.20464

Issue

Hepatology

Hepatology

Volume 40, Issue 6, pages 1421–1425, December 2004

Additional Information

How to Cite

van Bömmel, F., Wünsche, T., Mauss, S., Reinke, P., Bergk, A., Schürmann, D., Wiedenmann, B. and Berg, T. (2004), Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40: 1421–1425. doi: 10.1002/hep.20464

Author Information

  1. 1

    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité, Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany

  2. 2

    Medizinische Klinik mit Schwerpunkt Infektiologie und Asthma-Poliklinik, Charité, Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany

  3. 3

    Zentrum für HIV und Hepatogastroenterologie, Düsseldorf, Germany

  4. 4

    Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin, Charité, Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany

  1. ‡

    fax: (49) 30-450-553903

*Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

  1. †

    Presented in part at the 54th Annual Meeting of The American Association for the Study of Liver Diseases, October 24–28, 2003, Boston, MA (Abstract 246).

  2. ‡

    fax: (49) 30-450-553903

Publication History

  1. Issue published online: 24 NOV 2004
  2. Article first published online: 24 NOV 2004
  3. Manuscript Accepted: 23 AUG 2004
  4. Manuscript Received: 23 APR 2004

Funded by

  • the German BMBF Network of Competence for Viral Hepatitis (Hep Net)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (149K)

References

  • 1
    Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714–1722.
  • 2
    Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. HEPATOLOGY 2000; 32: 828–834.
    Direct Link:
  • 3
    Peters MG, Hann HwH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.
  • 4
    Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.
  • 5
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.
  • 6
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–807.
  • 7
    van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. HEPATOLOGY 2002; 36: 507–508.
    Direct Link:
  • 8
    Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352–2354.
  • 9
    Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186: 1844–1847.
  • 10
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 177–178.
  • 11
    van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124: 586–587
  • 12
    Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus “e-minus” patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17: 783–784.
  • 13
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185–1192.
  • 14
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266–272.
  • 15
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–297.
View Full Article (HTML) Get PDF (149K)